Payment overview · 2025
General Payments
$30,047.19
98 reported records · 12 companies
Healthcare provider profile · identity verified
Jay Mohan, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · MOUNT CLEMENS, MI · NPI 1366882656
Verified facts
What the public records show
CMS Open Payments records show Jay Mohan, DO received $30,047.19 in general payments during 2025 across 98 reported records.
Stryker Corporation accounted for 46.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $13,853.30 | 46.1% | 15 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$7,861.77 | 26.2% | 33 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $4,697.85 | 15.6% | 7 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $1,594.81 | 5.3% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $626.70 | 2.1% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $500.60 | 1.7% | 8 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $252.05 | 0.8% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $231.95 | 0.8% | 5 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $177.59 | 0.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $103.37 | 0.3% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $98.61 | 0.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.59 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $16,700.00 | 6 |
| Travel and Lodging | $8,532.72 | 11 |
| Food and Beverage | $4,814.47 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $13,387.77 | 7 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $13,387.77 | 7 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $4,697.85 | 7 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $1,470.25 | 9 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $956.23 | 14 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $410.92 | 4 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $267.14 | 4 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $231.95 | 5 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $215.34 | 4 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $206.45 | 3 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $160.64 | 1 | 2025 |
Source payment records
|
|||||
| Emerge Push Normalized: emerge push |
Device | Boston Scientific Corporation | $145.24 | 1 | 2025 |
Source payment records
|
|||||
| PRESSUREWIRE Normalized: pressurewire |
Device | Abbott Laboratories | $135.58 | 1 | 2025 |
Source payment records
|
|||||
| Eagle Eye Normalized: eagle eye |
Device | Philips North America LLC | $127.08 | 1 | 2025 |
Source payment records
|
|||||
| Encore Normalized: encore |
Device | Philips North America LLC | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $124.56 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $103.37 | 4 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $91.11 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $68.33 | 3 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $14.77 | 2 | 2025 |
Source payment records
|
|||||
| General - Angiography Normalized: general angiography |
Device | Boston Scientific Corporation | $2.21 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $1.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 345 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 338 | 109 |
| Clopidogrel | Clopidogrel Bisulfate | 323 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 285 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 63 |
| Furosemide | Furosemide | 196 | 73 |
| Carvedilol | Carvedilol | 193 | 61 |
| Lisinopril | Lisinopril | 193 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 157 | 52 |
| Losartan Potassium | Losartan Potassium | 147 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 47 |
| Xarelto | Rivaroxaban | 67 | 20 |
| Sotalol | Sotalol Hcl | 66 | 22 |
| Warfarin Sodium | Warfarin Sodium | 61 | 18 |
| Potassium Chloride | Potassium Chloride | 55 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 19 |
| Bumetanide | Bumetanide | 41 | 18 |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | 14 |
| Ranolazine Er | Ranolazine | 37 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 14 |
| Repatha Syringe | Evolocumab | 33 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 11 |
| Digoxin | Digoxin | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | 12 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30,047.19 · 98 records | Stryker Corporation | ABRE, ARTIX MT, AVEIR, Assure WCD, CLOTTRIEVER BOLD CATHETER, COROFLOW, CT THROMBECTOMY SYSTEM KIT, DRAGONFLY OPSTAR, ELUVIA, Eagle Eye, Emerge Push, Encore, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, General - Angiography, HAWKONE, Indigo System, JOT DX, LifeVest, PRESSUREWIRE, Penumbra System, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VENASEAL, WATCHMAN FLX, XIENCE SKYPOINT | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error